Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Bayer Apologizes for Employees’ “Improper” Involvement in Xarelto Survey, Whistleblower Says He Browsed Charts for over 200 Patients
April 12, 2017
- 1st Herceptin Biosimilar Filed in Japan: Nippon Kayaku
April 12, 2017
- Takeda Strikes Microbiome Deal with Canada’s NuBiyota
April 12, 2017
- Kyorin Gains Rights to Merck’s OAB Med in Asia
April 12, 2017
- Japan Authorized Generic Market Projected to Reach 81.7 Billion Yen in 2020: Fuji Keizai
April 11, 2017
- Takeda Sells Actos, Other Long-Listed Brands to Teva JV
April 11, 2017
- Ethical Drug Sales Sag 11.3% in February: Crecon
April 11, 2017
- Sumitomo Dainippon Gives Bukwang Korean Rights for Lurasidone
April 11, 2017
- Santen Makes Strategic Investment in US Cell Therapy Technology Firm
April 10, 2017
- Mogamulizumab Hits Primary Endpoint in PIII for CTCL: Kyowa Kirin
April 10, 2017
- Kyowa Kirin’s KRN23 Delivers Positive PII Data for Pediatric X-Linked Hypophosphatemia
April 10, 2017
- Takeda-PRA Joint Venture in Japan to Be Formed on June 1
April 10, 2017
- Trerief Delivers Positive Results in Lewy Body Dementia: Sumitomo Dainippon
April 7, 2017
- Boehringer Japan to Spur Joint Drug Discovery Research, Eyes 1st Clinical Trial in 2020
April 7, 2017
- Takeda Earns Global Rights to Finch’s Microbiome IBD Therapy
April 7, 2017
- Takeda’s Massive Dengue Trial Enrollment Completed
April 7, 2017
- Heptares Gains Preclinical Milestone in AZ Immuno-Oncology Deal
April 6, 2017
- Eisai Gets Japan, Asian Rights to Safinamide from Meiji
April 6, 2017
- Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility
April 6, 2017
- Mochida Aims for Sales of 107 Billion Yen in FY2017 under New 3 Year Biz Plan
April 5, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…